Association of Race and Ethnicity with Genomic Testing at a Comprehensive Cancer Center in North Carolina
Non-Hispanic Black patients diagnosed with prostate cancer between 2014 and 2019 and treated at a comprehensive cancer center were less likely to use tumor-specific genomic testing compared with non-Hispanic White patients. Disparities in the use of precision oncology technologies should be monitored and addressed to ensure equitable cancer care.
Authors
- John H. Strickler (ORCID: https://orcid.org/0000-0001-7579-1175)
- Hayden B. Bosworth (ORCID: https://orcid.org/0000-0001-6188-9825)
- Clare Meernik (ORCID: https://orcid.org/0000-0002-8564-1266)
- Devon K. Check (ORCID: https://orcid.org/0000-0002-0673-879X)
- Linda Sutton
- Frances Wang (ORCID: https://orcid.org/0009-0006-2015-0796)
- Tomi Akinyemiju (ORCID: https://orcid.org/0000-0002-1412-3234)
- Yadurshini Raveendran (ORCID: https://orcid.org/0000-0002-0523-0097)
- Michelle Green (ORCID: https://orcid.org/0000-0002-6055-4342)
Institutions
- Duke University (US)
- Duke Medical Center (US)
- Durham VA Medical Center (US)
- Duke University Hospital (US)
Publication Details
- Journal
- Cancer Research Communications
- Published
- 2024-10-23
- DOI
- https://doi.org/10.1158/2767-9764.crc-24-0134
- Citations
- 3
- Primary Topic
- BRCA gene mutations in cancer
- Type
- article
- Field-Weighted Citation Impact
- 1.65
Funders
- Pfizer
- Sanofi
- Novo Nordisk
- Esperion Therapeutics
- National Heart, Lung, and Blood Institute